hrp0094p1-161 | Growth B | ESPE2021

Continued Safety and Efficacy of Weekly Lonapegsomatropin (TransCon hGH) for up to Two Years in Children with Growth Hormone Deficiency (GHD)

Aghajanova Elena M. , Casella Samuel J. , Nadgir Ulhas , Hofman Paul , Saenger Paul , Song Wenjie , Mao Meng , Chessler Steven , Komirenko Allison S. , Beckert Michael , Shu Aimee D. , Thornton Paul S. , Maniatis Aristides K. ,

Lonapegsomatropin (TransCon hGH) is an investigational once-weekly prodrug of somatropin for the treatment of GHD. Previous trials in treatment-naïve (52-week heiGHt Trial) and treatment-experienced children (26-week fliGHt Trial) have reported the efficacy and safety of lonapegsomatropin. Subjects were eligible to enter the open-label extension enliGHten Trial, which continues to evaluate weekly lonapegsomatropin in pediatric GHD. In heiGHt, treatment-naïve subjects...

hrp0089p2-p219 | GH & IGFs P2 | ESPE2018

Baseline Demographics of the TransCon GH Phase 3 heiGHt Trial

Beckert Michael , Karpf David B , Shu Aimee , Lin Zhengning , Leff Jonathan A

Background: TransCon GH is a novel sustained-release recombinant human GH (somatropin) prodrug in development for children with GH deficiency (GHD). It is designed to release unmodified GH and intended to provide comparable efficacy, safety, tolerability, and immunogenicity to daily GH with once-weekly dosing. Based on results from a phase 2 trial, which demonstrated comparable efficacy (annualized height velocity for TransCon 0.21 mg GH/kg per week of 12.9 cm/year vs 11.6 cm/...

hrp0097lb17 | Late Breaking | ESPE2023

The Majority of Children with Pediatric Growth Hormone Deficiency Treated With Lonapegsomatropin for Up To 6 Years Met or Exceeded Average Parental Height SDS: Final Results of enliGHten

Vlachopapadopoulou Elpis , Thornton Paul , Hofman Paul , Nadgir Ulhas , Saenger Paul , Malievskiy Oleg , Aghajanova Elena , Korpal-Szczyrska Maria , Mao Meng , Abdelrahman Sohair , Komirenko Allison , Shu Aimee , Maniatis Aristides

Introduction: Lonapegsomatropin (SKYTROFA, TransCon hGH), a prodrug of somatropin administered once-weekly, is approved for the treatment of pediatric growth hormone deficiency (GHD) by the Food and Drug Administration and European Commission. In the pivotal 52-week phase 3 heiGHt trial and 26-week fliGHt trial (enrolled treatment-naïve and treatment-experienced participants, respectively), lonapegsomatropin demonstrated safety and efficacy in children wi...

hrp0092fc14.4 | GH and IGF4 | ESPE2019

Once-Weekly TransCon hGH vs. Daily hGH in Pediatric Growth Hormone Deficiency: The Phase 3 heiGHt Trial

Vlachopapadopoulou Elpis , Aghajanova Elena , Chertok Elena , Korpal-Szczyrska Maria , Giorgadze Elene , Kovalenko Tatiana , Maniatis Aristedes , Thornton Paul , Hofman Paul , Song Wenjie , Shu Aimee , Karpf David , Beckert Michael , Leff Jonathan

Background: TransCon hGH is a sustained-release prodrug in development as a long-acting GH for children with growth hormone deficiency (GHD). TransCon hGH consists of a parent drug, growth hormone (hGH; somatropin), that is transiently bound to a carrier via a TransCon linker. The carrier extends hGH circulation time in the body and fully active hGH is released over one week at physiologic pH and temperature. Unlike other molecules in development, TransCon hGH...

hrp0094fc7.2 | Fetal Endocrinology and Multisystem Disorders | ESPE2021

Maternal, rather than fetal, genetic variation in vitamin D metabolism is associated with umbilical cord blood 25-hydroxyvitamin D in pregnancies supplemented with cholecalciferol: findings from the MAVIDOS randomized controlled trial

Moon Rebecca , D’Angelo Stefania , Curtis Elizabeth , Cooke Laura , Davies Justin , Crozier Sarah , Godfrey Keith , Graham Nikki , Holloway John , Lewis Rohan , Cleal Jane , Inskip Hazel , Cooper Cyrus ,

Background: Neonatal vitamin D deficiency (VDD) can result in symptomatic hypocalcemia, seizures and cardiomyopathy and has been associated with reduced bone mineralization in childhood, but is potentially preventable with antenatal cholecalciferol supplementation. Single nucleotide polymorphisms (SNP) in the vitamin D metabolism pathway are associated with serum 25-hydroxyvitamin D [25(OH)D] in adulthood. We assessed whether maternal and/or offspring SNPs in ...

hrp0089p1-p026 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Duration of Breastfeeding and Bone Mineral Density in Childhood – A Prospective Study Among Preschool Children

Tint Mya Thway , Pang Wei Wei , Vasanwala Rashida Farhad , Padmapriya Natarajan , Ng Sharon , Soh Shu E , Chong Mary Fong-Fong , Shek Lynette Pei Chi , Gluckman Peter D , Chong Yap-Seng , Godfrey Keith M , Fortier Marielle V , Eriksson Johan G , Lee Yung Seng , Zhang Cuilin , Yap Fabian

Background: Bone growth and mineralization during childhood are now recognized as important for bone health in adulthood, leading to renewed interest in identifying modifiable factors that impact bone mineral density (BMD) in childhood. Emerging data suggest that duration of breastfeeding may affect BMD in later childhood and adult life. However, such data are sparse and inconsistent.Objectives: This study examined the relationship betwe...

hrp0094s11.2 | Calcium and Phosphate Beyond Bone | ESPE2021

Vitamin D and male reproduction

Blomberg Jensen Martin ,

Newer studies have indicated that vitamin D has more widespread effects than the classical effects on bone and calcium-phosphate homeostasis. The presence of the vitamin D receptor (VDR) in the testis and male reproductive tract indicates a role for vitamin D in male reproduction. Indeed, vitamin D deficiency and global knock out models of VDR or CYP27B1 in rodents have shown that vitamin D and calcium are important regulators of male reproductive function. Several groups have...

hrp0089rfc2.3 | Bone, Growth Plate & Mineral Metabolism 1 | ESPE2018

Measured Free 25-Hydroxyvitamin D in Healthy Children and Relationship to Total 25-Hydroxyvitamin D, Calculated Free 25-Hydroxyvitamin D and Vitamin D Binding Protein

Bosch i Ara Laura , Lopez-Molina Maria , Santillan Cecilia , Murillo Marta , Valls Aina , Bel Joan

Introduction: Vitamin D deficiency in children is still a global health problem. Measuring free 25-hydroxyvitamin D concentrations could provide a better estimate of the vitamin D status than total 25-hydroxyvitamin D (25(OH)D) levels.Objective: To assess the relationship between measured free vitamin D (m-f25(OH)D) and calculated free 25(OH)D (c-f25(OH)D), total 25(OH)D, intact parathyroid hormone (iPTH) and other markers of phosphocalcic metabolism. Es...

hrp0082p3-d3-692 | Bone (2) | ESPE2014

Vitamin D Deficiency in Children

Dobrescu Andreea , Chirita-Emandi Adela , Papa Maria , Puiu Maria

Background: Vitamin D deficiency has a high prevalence in children. It is produced by the skin from exposure to sunlight but its synthesis is influenced by many external and internal factors.Objective and hypotheses: The study aims to evaluate vitamin D in children with different pathology and highlights the influencing factors of it.Method: We evaluate 25-hydroxyvitamin D levels in 84 patients, sex ratio 1.15:1, aged between 3 mon...

hrp0084p3-1018 | Growth | ESPE2015

Vitamin D in Short Children on GH Therapy: Effects of Vitamin D Status and Vitamin D Supplementation on Glucose Homeostasis

Dumitrescu Cristina , Caragheorgheopol Andra , Gherlan Iuliana , Brehar Andreea , Padure Adriana , Olaru Maria , Procopiuc Camelia

Background: Glucose metabolism effects of vitamin D deficiency are debated. GH therapy is associated with increased insulin values and decreased insulin sensitivity.Objective and hypotheses: To investigate vitamin D status in short children treated with GH- to investigate if the known effects of GH therapy on glucose metabolism are modulated by vitamin D supplementation.Method: 41 children treated with GH for short stature where ev...